Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (proximal tubule cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | Reactome did not answer (Reactome: The operation was aborted due to timeout) | 0.00 |
No case: the score is under the bar. Receipt 14397
Sealed predictions
- XKR9 in dopamine neurons, braak-0.11 (p 0.773) → +0.29 (p 0.443)receipt 14404
Swarm cases
receipt 14404: XKR9 in dopamine neurons, braak
- power
- full sample +0.10 (p 0.683, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.696, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.515, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.26, sign flips 1; without severely affected donors +0.10 (p 0.683, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for XKR9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts